Recurrent thrombosis followed by Lazarus response in ROS1 rearranged NSCLC treated with crizotinib: a case report.
Teresa BeninatoGiuseppe Lo RussoMarina Chiara GarassinoFilippo De BraudMarco PlataniaPublished in: Tumori (2020)
Cancer diagnosis should always be considered in patients with unprovoked thrombosis and, if NSCLC is diagnosed, genetic alterations should be always sought after. A possible relation between venous thromboembolism and oncogenic drivers, particularly for ALK translocations, has been hypothesized. Similarly to ALK-positive NSCLC, ROS1 rearranged disease has been associated with an increased thromboembolic risk. Further studies are needed to better evaluate this relation and to evaluate the potential benefit of a prophylactic anticoagulating treatment in this subset of patients.
Keyphrases
- advanced non small cell lung cancer
- venous thromboembolism
- small cell lung cancer
- epidermal growth factor receptor
- end stage renal disease
- newly diagnosed
- pulmonary embolism
- dna damage
- cell death
- ejection fraction
- direct oral anticoagulants
- reactive oxygen species
- peritoneal dialysis
- chronic kidney disease
- prognostic factors
- squamous cell carcinoma
- gene expression
- patient reported outcomes
- oxidative stress
- copy number
- climate change
- human health